Dr. Chapa’s OBGYN Clinical Pearls

00:16:57

“Expression of Concern” Over a Green Journal Article

Dr. Chapa’s OBGYN Clinical Pearls ·

2026/01/24

Back in March of 2025, the green journal (obstetrics andgynecology) published A systematic review and meta-analysis on 2 medications (non-hormonal) and their efficacy in menopausal hot flash relief period these medications were Fezolinetant and Elinzanetant. However, the editors have just recently released an “Expression of Concern” about this review. Listen in for details. 1. Menegaz de Almeida, Artur MS; Oliveira, PalomaMS; Lopes, Lucca MD; Leite, Marianna MS; Morbach, Victória MS; Alves

en

00:12:45

FDA’s ENG Label Change: What To Know

Dr. Chapa’s OBGYN Clinical Pearls ·

2026/01/23

Implanon (etonogestrel implant) first received FDA approval in 2006, followed by the improved, radiopaque version, Nexplanon, approved by the FDA in 2010, which is now the only contraceptive implant available in the U.S. It was originally FDA approved for a 3-year use duration, although peer reviewed clinical data had demonstrated efficacy through year 5. Now, as of January 2026, the FDA has formally agreed to extend the label for 5-year use. In this episode, we will review the clinical data that

en

00:37:46

Does Ursodiol Reduce Adverse Outcomes in ICP?

Dr. Chapa’s OBGYN Clinical Pearls ·

2026/01/21

Ursodiol (ursodeoxycholic acid) is a prescription bile acid medication used to dissolve cholesterol gallstones, prevent gallstones during rapid weight loss, and treat liver diseases like primary biliary cholangitis (PBC) by reducing toxic bile acids and cholesterol production. It works by changing bile composition, making it less saturated with cholesterol, and is available as oral medication. Of course, it is also the foundational medication for treatment of diagnosed Intrahepatic Cholestasis of

en

00:26:56

New CC #11: Positive HCG in the Non-OB/Non-Gyn CA...

Dr. Chapa’s OBGYN Clinical Pearls ·

2026/01/18

HCG is a heterodimeric glycoprotein typically produced by trophoblastic tissue. However, there are occasions where a serum HCG is obtained that remains low level POSITIVE, yet the patient is not pregnant, nor does she have a gynecologic malignancy. Why dose this happen. Not all these instances can be explained by the “PHANTOM” HCG. In this episode, we will review a new Clinical Consensus guideline from the ACOG officially being released in Feb 2026. Like the finding of an aberrant aneuploidy on

en

00:23:07

TXA for ENG Implant Bleeding?

Dr. Chapa’s OBGYN Clinical Pearls ·

2026/01/16

The ENG implant has data placing it as the most reversible, hormonal contraceptive agent available with a typical use failure rate of 0.05%. Unfavorable bleeding patterns, such as frequent or prolonged bleeding, affect approximately 40% of ENG implant users within the first 3 months but typically improve over time. Nonetheless, it is the main reason for patient discontinuation. In the past, various medications have shown to have at least some short-term reduction in bothersome breakthrough bleeding

en

00:33:03

Does Uterine Incision-to-Delivery Interval Matter?

Dr. Chapa’s OBGYN Clinical Pearls ·

2026/01/13

It’s a controversial topic: the impact of uterine incision (hysterectomy) on the neonate delivery interval (also called the U-D interval). Does it matter? Just to be clear, we’re talking about time from uterine entry to fetal extraction, not skin incision to fetal extraction. Past publications have produced conflicting results, often limited by small sample sizes, heterogeneous indications for delivery, and reliance on surrogate markers (like apgar scores) rather than clinical morbidity. But a new

en

00:37:09

cfDNA: Jan 2026 Practice Advisory

Dr. Chapa’s OBGYN Clinical Pearls ·

2026/01/10

In January 2026, the ACOG released its Practice Advisory on Screening for fetal Chromosomal Abnormalities. This comes after its Nov 2025 endorsement of the SMFM’s Consult Series #74, “Cell-free DNA screening for aneuploidies: Updated guidance”. In this episode we will review the key parts of this PA. Is screening for microdeletions recommended? PLUS, we will focus on cfDNA for sex chromosomal abnormalities. Should screening for sex chromosomal abnormalities (SCAs) be an “opt in” or “opt out” process

en

00:33:46

TOLAC, PIT, and Internals: The Latest

Dr. Chapa’s OBGYN Clinical Pearls ·

2026/01/08

Uterine rupture or dehiscence associated with TOLAC results in the most significant increase in the likelihood of additional maternal and neonatal morbidity. It should be noted that the terms “uterine rupture” and “uterine dehiscence” are not consistently distinguished from each other in the literature and often are used interchangeably. Furthermore, the reported incidence of uterine rupture varies in part because some studies have grouped true, catastrophic uterine rupture together with

en

00:27:50

The 2025 Big Baby Trial

Dr. Chapa’s OBGYN Clinical Pearls ·

2026/01/05

Currently, as of today’s date, neither the ACOG nor SMFM currently support routine early induction of labor for suspected fetal macrosomia, instead recommending individualized counseling and reserving elective cesarean for extreme estimated fetal weights. However, a 2025 multicenter, open-label, randomized controlled trial was published in the Lancet comparing induction of labor versus standard care in pregnant women with fetuses suspected to be large for gestational age. The study used a

en

00:26:15

Brain Zapping at Home Now Approved!

Dr. Chapa’s OBGYN Clinical Pearls ·

2026/01/02

In mid-December 2025, the FDA approved an at home devicethat aims to treat depression by sending electric current into a part of the brain (the prefrontal cortex) known to regulate mood. This has been available in the UK since 2019 but it is new to the US. The manufacturer has stated that over 55,000 patients have used the device across Europe, the UK, Switzerland, and Hong Kong. How does this work? Is there data to support this new therapy? In this episode, we will summarize three consecutive years

en

00:32:00

New Data on VO-CPP (PeVD) Therapy

Dr. Chapa’s OBGYN Clinical Pearls ·

2025/12/30

While endometriosis is highly associated with Chronic Pelvic Pian (CPP), some women may suffer from a different primary or coexistent secondary etiology: pelvic vascular congestion, called vascular origin (VO)- CPP. Although controversial as an entity, there have been diagnostic algorithms published (via pelvic ultrasound. MRI, or venography) for this condition. Approximately 10-40% of chronic pelvic pain cases may be attributed to pelvic vascular congestion (now termed pelvic venous disorder),

en

00:01:06

Emily's Thanks to You

Dr. Chapa’s OBGYN Clinical Pearls ·

2025/12/28

A brief THANK YOU prior to 2025 end.

en

00:24:10

FHT Baseline Change (110-160) in Labor: Danger, or...

Dr. Chapa’s OBGYN Clinical Pearls ·

2025/12/27

In 2002, the National Institute of Child Health and Human Development (NICHD) proposed the 3-Tier fetal heart rate (FHR) classification system that was subsequently adopted by many organizations, categorizing tracings into three groups: Category I (normal), Category II (indeterminate), and Category III (abnormal). Recently, our podcast team received an interesting question form one of our podcast family members: “If there is a change in the fetal heart rate tracing intrapartum, but it is still in

en

00:19:29

PFM Question: IAI WITHOUT Fever?

Dr. Chapa’s OBGYN Clinical Pearls ·

2025/12/24

Podcast Family, in our immediate past episode we tackled the discrepancy that is often found between a clinical diagnosis of intra-amniotic infection/chorioamnionitis and histological chorioamnionitis. From that episode, we received a fantastic question from one of our podcast family members: Can a patient have IAI without fever? That question is really deep and highlights a gap in the current diagnostic scheme/ criteria from the ACOG. Listen in for details!1. ACOG CO 7122. Sukumaran S, Pereira V,

en

00:23:36

Chorio Paradox: When Clinical & Path DX Don’t Agree

Dr. Chapa’s OBGYN Clinical Pearls ·

2025/12/21

Welcome to "Labor & Delivery Debrief," the podcast where we tackle your toughest questions about childbirth and maternal health. Today, we're diving deep into a fascinating and critical topic sent in by one of our listeners, Sarah. Sarah asks: "Is it possible for a clinical diagnosis of chorioamnionitis to not be confirmed by placental histology? And if so, how is that possible?" This is a fantastic question that touches on the complexities of intrapartum clinical diagnosis of intraamniotic

en

00:20:33

WARNING: DepoP and Meningiomas

Dr. Chapa’s OBGYN Clinical Pearls ·

2025/12/18

Depo-Provera was approved in 1992 by U.S. regulators. About 1 in 4 sexually active women in the United States have used the shot at some point, according to the U.S. Centers for Disease Control and Prevention (CDC). Meningiomas are common intracranial tumors with a female predominance. In fact, they are the most common primary brain tumor in women, with an incidence of approximately 12.76 per 100,000 in the general female population. The vast majority of these tumors are benign (World Health

en

00:19:11

Lube It Up For Baby Delivery?

Dr. Chapa’s OBGYN Clinical Pearls ·

2025/12/17

The second stage of labor, characterized by active pushing and the descent of the fetal head, can be a challenging and prolonged phase for both mother and baby. Various interventions have been explored to optimize this stage, and one such technique involves the application of vaginal lubricants. The rationale behind this approach is to reduce friction between the fetal head and the birth canal, potentially leading to smoother and faster delivery. Does this seemingly simple technique work? Does the

en

00:13:50

The 2 New FDA Approved GC Meds

Dr. Chapa’s OBGYN Clinical Pearls ·

2025/12/15

Within the last few days, there has been breaking news regarding the war on gonorrhea. Nuzolvence (zoliflodacin) was FDA approved on December 13, 2025, and Blujepa (gepotidacin) was FDA approved on December 11, 2025.These new oral treatments are particularly important given the global rise in gonococcal drug resistance and the convenience they offer over injectable options, potentially improving patient adherence and public health outcomes. Listen in for details. FDA News Release. FDA Approves Two

en

00:16:24

Delayed Cord Clamping UPDATE (With Med Student Guest...

Dr. Chapa’s OBGYN Clinical Pearls ·

2025/12/13

It’s so interesting to see how medical evidence evolves, and changes, over time. The result of course is that clinical practice evolves and changes as well. The story of umbilical cord management at time of delivery highlights this very issue very well. The ACOG first recommended delayed cord clamping (DCC) in 2012, for preterm infants, as data showed marked improvement in neonatal outcomes in that population. In this episode, we will briefly walk through the timeline from 2012 to the latest update

en

00:24:38

Continue Metformin in 1st T for PCOS?

Dr. Chapa’s OBGYN Clinical Pearls ·

2025/12/11

Podcast Family, we have covered PCOS on this show many times in the past; and yet- again, there is new information! A new publication from AJOG (Gray journal) describes a new meta-analysis on preconception/continued metformin use in the first trimester. Is this helpful? How does this contrast with the 2023 international guidance update on PCOS? Listen in for details. 1. ASRM: Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary

en

All Episodes

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

Show Me the Science with Luke O"Neill

Newstalk

Planetterrian Daily

Patrick · Nerra Network

Sleep Science

Sleep Science

BioSpace

BioSpace